Colostrum as a Protective Factor Against Peanut Allergy: Evidence From a Birth Cohort

Maheshwar Bhasin1,2, Matthew Cooper2, Patricia Macchiaverni1,2

  • 1Larsson-Rosenquist Foundation Centre for Immunology and Breastfeeding, School of Medicine, University of Western Australia, Perth, Western Australia, Australia.

Allergy
|September 19, 2025
PubMed

Insights

Partial colostrum feeding, where infants receive formula alongside breast milk, is linked to a higher risk of peanut and multiple food allergies. Ensuring adequate colostrum intake may be crucial for preventing allergies in newborns.

Area of Science:

  • Immunology
  • Pediatrics
  • Allergy Research

Background:

  • Food allergies pose significant risks to quality of life and can be life-threatening.
  • Early life feeding practices are crucial for immune development and allergy prevention.
  • Colostrum, rich in bioactive compounds, plays a vital role in infant immune and gut health.

Purpose of the Study:

  • To investigate if partial colostrum feeding (PCF) increases the risk of food allergy.
  • To determine the association between colostrum intake and allergic outcomes.
  • To identify early modifiable risk factors for food allergies.

Main Methods:

  • Studied 666 mother-infant pairs from the Australian ORIGINS cohort.
  • Categorized neonates into exclusive colostrum-fed (ECF) or partial colostrum-fed (PCF) groups within the first 3 days.
  • Assessed IgE-mediated food allergy at 12-18 months using skin prick tests and maternal reports.

Main Results:

  • 46% of infants were partially colostrum-fed (PCF).
  • PCF infants showed significantly increased risk for peanut allergy (aOR 4.47) and multiple food allergies (aOR 11.44).
  • No peanut allergy cases occurred in infants receiving ≥9 colostrum feeds/day within 72 hours, irrespective of formula use.

Conclusions:

  • Partial colostrum feeding is an overlooked risk factor for peanut and multiple food allergies.
  • Promoting colostrum feeding is essential for allergy prevention in newborns.
  • Colostrum-based therapies may benefit high-risk infants.
Abstract